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1. Introduction  
Although significant progress in the investigation of prostate cancer biomarkers, some men 
are overdiagnosed with indolent prostate cancer while others die from aggressive disease 
diagnosed too late. The introduction of PSA (Prostate Specific Antigen) in clinical practice 
has resulted in early detection and reduced mortality from prostate cancer (Schroder et al., 
2009). Despite its great utility for prostate cancer detection and prognostication, PSA as a 
single test has several limitations. Prostate cancer screening remains thus controversial, 
because of the risk of overdiagnosis reduced mortality and overtreatment and the inability 
to detect a significant proportion of aggressive tumors. To extend the limited information 
provided by PSA testing, other biomarkers that could discriminate between indolent from 
aggressive cancers are therefore an absolute must. Despite numerous studies of biomarker 
candidates have been presented the last decade, the identification of the most aggressive 
subsets of this disease is still not possible. This review will cover last years development in 
this area and highlight the most promising biomarkers in prostate cancer, which have been 
divided into three groups; protein-based, DNA-based and RNA-based markers. 
2. Protein biomarkers 
2.1 Prostate Stem Cell Antigen (PSCA) 
PSCA (Prostate Stem Cell Antigen) is a membrane glycoprotein with 30% homology to stem 
cell antigen type 2 (SCA-2), an immature lymphocyte cell surface marker. Like SCA-2, PSCA 
is attached to the membrane by a GPI anchor which can be cleaved by a phospholipase. 
Because of its homology with SCA-2, PSCA was named inaccurately since it is not a marker 
for stem cells nor is it uniquely expressed in the prostate (Saeki et al., 2010). Initially, PSCA 
was identified as a tumor antigen overexpressed in the prostate (Reiter et al., 1998), and 
subsequent studies have revealed that it is also up-regulated in other cancers including 
bladder and pancreas. PSCA has been proposed as a promising tumor marker of diagnostic 
and prognosis, as well as a potential therapeutic target for patients with metastatic prostate 
cancer. PSCA expression indeed increases with high gleason score, advanced stage and bone 
metastasis (Gu et al., 2000; Han et al., 2004; Lam et al., 2005; Zhigang & Wenlv, 2004). The 
levels of PSCA are also amplified in the prostate intraepithelial neoplasia (PIN) lesions that 
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subsequently progressed to cancer compared to those that did not progress (Zhigang & 
Wenlu, 2007). PSCA might also represent a useful marker for metastasis detection as almost 
95% of lymph nodes and bone samples with metastasis have been found positive for PSCA 
expression (Ananias et al., 2009). It was originally observed that PSCA mRNA bearing cells 
circulating in peripheral blood were identified at higher rates in prostate cancer patients 
with extraprostatic disease (Hara et al., 2002). The presence of PSCA transcripts in the 
peripheral blood has found to be a significant predictor of biochemical recurrence after 
prostatectomy in high-risk prostate cancer (Joung et al., 2010). Of note, PSCA has also been 
investigated as a potential target for tumor-targeted immunotherapy and for suppression by 
anti-PSCA antibody in animals. Further evaluation of PSCA as a clinical prostate cancer 
marker of aggressiveness needs to be validated. 
2.2 Prostate Secretory Protein 94 (PSP94) 
The ELISA dosage of ǃ-microseminoprotein (MSP) ou PSP94 (Prostate Secretory Protein of 
94 amino acids) – one of three predominant proteins secreted by the human prostate gland 
(Lilja & Abrahamsson, 1988) – could be potentially interesting. In a case-control study of 
1,212 men with no previous history of prostate cancer, Nam et al. found that patients with 
low PSP94 levels had a high probability for having prostate cancer diagnosed at biopsy 
(Nam et al., 2006). The authors also suggested that those cancers that maintain PSP94 
expression tend to be well differentiated and less aggressive, as reported in previous 
immunohistochemistry studies (Abrahamsson et al., 1988). In serum, PSP94 can be 
complexed with PSPBP (PSP-binding protein), a glycoprotein of 50 kDa sharing significant 
identity with the CRISP (cystein-rich seccretory protein) family of proteins (Reeves et al., 
2005). In a study comprising 185 patients, it was showed that PSPBP is negatively associated 
with recurrence after radical prostatectomy (Reeves et al., 2006). On the contrary, PSP94 
immunohistochemistry performed on 59 radical prostatectomy specimens was associated 
with worsened survival outcomes (Girvan et al., 2005). Another immunohistochemistry 
study conducted on 945 patients found a high expression of PSP94 in tumor cells patients to 
be associated with a longer time to postprostatectomy biochemical recurrence (Bjartell et al., 
2007) in agreement with serum studies. Further studies will be needed to determine whether 
PSP94 and its binding protein represent novel prognostic factors in the clinic.  
However, it is interesting to note that genome-wide association studies identified several 
SNPs in a region on chromosome 10 that harbors the PSP94 gene (Eeles et al., 2008; Thomas 
et al., 2008). Its location and the strength of the association raises the possibility that this 
SNP may be causally related to disease risk, but resequencing and further analyses will be 
needed clarify the functional basis of this association. 
2.3 Early Prostate Cancer Antigens ECPA and ECPA-2 
ECPA and ECPA-2 (Early Prostate Cancer Antigens) are nuclear matrix proteins those 
alterations are commonly associated with prostate cancer (Getzenberg et al., 1991; 
Lakshmanan et al., 1998). Initially, immunohistochemical studies on men with negative 
biopsies who were ultimately found to have prostate cancer could identify individuals as 
much as 5 years earlier than the current diagnostic (Dhir et al., 2004). ECPA positivity was 
hypothesized to be an early event in disease progression, as there was no correlation 
between ECPA staining and Gleason grade or pT stage (Uetsuki et al., 2005). In 2005, an 
ECPA-based ELISA showed 92% sensitivity and 94% specificity in prostate cancer detection 
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in patients undergoing radical prostatectomy, however only 46 blood samples were 
examined (Paul et al., 2005). ELISA used for initial serum EPCA measurement in 112 men 
with isolated high-grade prostatic intraepithelial neoplasia (HGPIN), showed a significantly 
higher serum ECPA level in isolated HGPIN patients with subsequent cancer than those 
without cancer (Zhao & Zeng, 2010). Pretreatment serum EPCA levels were also determined 
with an ELISA in 77 patients with clinically localized prostate cancer who underwent radical 
prostatectomy and 51 patients with locally advanced or metastatic disease who received 
primary androgen deprivation therapy, and were correlated with clinicopathological 
variables and disease progression. Patients with locally advanced and metastatic prostate 
cancer had significantly higher serum EPCA level than those with clinically localized 
disease. These data suggest that EPCA level correlates significantly with the poor prognosis, 
showing prediction potential for prostate cancer progression (Zhao et al., 2011). Unrelated to 
the original ECPA, the nuclear protein ECPA-2 was recently described (Leman et al., 2007). 
Carried out on 385 blood samples, the ECPA-2 ELISA was able to differentiate between men 
with and without prostate cancer with 92% specificity and 94% sensitivity, whereas the 
specificity of PSA was only 65% in the same population (Leman et al., 2007). More 
importantly, in contrast to PSA, ECPA-2 is able to discriminate men with non-organ-
confined prostate cancer from those with organ-confined diseases. Although additional 
validation studies are needed to show the performance of ECPA-2 in a more representative 
population, these results lend support to the development of a more accurate blood-based 
assay to identify aggressive prostate cancer. 
2.4 uPA/uPAR 
A wealth of reports suggest a key role for the urokinase-type plasminogen activator and its 
receptor (uPA/uPAR) in invasion and metastatic dissemination (Duffy, 2004). uPA is is a 
member of the serine protease family synthetized and secreted as a pro-enzyme, whose 
activation is markedly accelerated upon binding with high affinity to specific membrane-
bound or soluble cell surface uPAR. Once activated, the uPA/uPAR system efficiently 
converts plasminogen into plasmin, a protease which then modulates extracellular matrix 
degradation, tumor cell invasion and growth factor activation (Duffy, 2004). In prostate 
cancer, overexpression of uPA and uPAR (transcripts and proteins) have been reported in 
tumor tissues suggesting that both proteins could be associated with tumor progression. 
Immunohistochemical studies have shown an incremental increase in uPA/uPAR 
expression from benign epithelium to primary organ-confined prostate cancer, to disease 
extending beyond the prostate capsule, and to bone metastases (Cozzi et al., 2006; Gavrilov 
et al., 2001; Pulukuri et al., 2007; Usher et al., 2005). In addition, overexpression of uPA and 
its inhibitor PAI-1 are associated with aggressive prostate cancer recurrence in men treated 
with radical prostatectomy (Gupta et al., 2009). Elevated circulating levels of uPA and/or 
uPAR have been associated with advanced prostate cancer and bone metastases (Hienert et 
al., 1988a; Hienert et al., 1988b; Miyake et al., 1999). Shariat et al. have recently reported that 
plasma levels of uPA and uPAR are not only higher in men with prostate cancer than in 
healthy controls, but decrease significantly after prostatectomy (suggesting that direct local 
production by malignant cells significantly contributes to increased uPA and uPAR 
circulating levels of these markers in patients), then increase with disease progression 
(Shariat et al., 2007). Of note, higher preoperative uPA and uPAR were both significantly 
associated with shorter progression PSA doubling times, failure to respond to salvage local 
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radiation therapy, and /or development of distant metastases (Shariat et al., 2007). Larger 
studies are needed to validate the promising role of uPA and uPAR as biomarkers of 
aggressive prostate cancer. 
3. DNA biomarkers 
3.1 Epigenetic markers 
Epigenetic alterations, i.e., alterations in gene expression without changes in the DNA 
sequence, include global genomic hypomethylation, promoter hypermethylation of CpG 
islands and loss of imprinting. The most common somatic genome alteration during 
prostate cancer development appears to be the hypermethylation in the regulatory region of 
certain genes, most commonly in the promoter of the π-class glutathione-S-transferase 
(GSTP1) gene (Lee et al., 1994). GSTP1 is a member of a large family of glutathione 
transferases that protect DNA from free radicals (Hayes & Strange, 1995). Men with a 
positive preoperative serum analysis for GSTP1 CpG island hypermethylation were at 
significant risk to experience PSA recurrence within the first several years following radical 
prostatectomy (Bastian et al., 2005). A high frequency of GSTP1 methylation in the urine of 
men with high-stage cancer was also recently reported (Woodson et al., 2008). Other 
candidate genes have been examined for hypermethylation along with GSTP1. A recent 
study suggested that men with advanced prostate cancer and biochemical recurrence 
experience a significant increase in promoter hypermethylation between initial diagnosis 
(first blood analysis) and time to progression (second blood analysis) in the four genes with 
the highest methylation frequencies (GSTP1, APC, RARǃ2 and RASSF1ǂ) in prostate cancer 
patients compared to age-matched controls (Roupret et al., 2008). This study suggests that 
multiple gene methylation analysis in circulating cell DNA could be a good biomarker for 
early detection of prostate cancer recurrence. 
3.2 Gene fusion proteins 
Based on a bioinformatics strategy Tomlins et al. described for the first time in prostate 
cancer a series of genetic rearrangements between the 5’-untranslated region of TMPRSS2 
(21q22) and some members of the ETS family of transcription factors, such as ERG (21q22), 
ETV1 (7p21) and ETV4 (17q21), which have important roles in several oncogenic pathways 
(Tomlins et al., 2005). Approximatively 50% of prostate cancers from serum PSA-screened 
cohorts harbor recurrent gene fusions (Kumar-Sinha et al., 2008), which can be detected by 
fluorescent in situ hybridisation (FISH). Conflicting results have been reported regarding the 
prognosis value of prostate cancer harboring TMPRESS2:ERG gene fusions. Earlier studies 
reported associations with high stage, metastasis, and prostate cancer-specific death (Attard 
et al., 2008; Demichelis et al., 2007; Nam et al., 2007), but more recent reports found no 
association with outcome (Gopalan et al., 2009; Leinonen et al., 2010; Mehra et al., 2007), an 
association with favorable outcome (Saramaki et al., 2008), or a similar percentage of 
TMPRSS2:ERG gene fusion in minute and nonminute adenocarcinomas (Albadine et al., 
2009), all suggesting its lack of value as a marker of aggressive prostate cancer. The analysis 
of the relationship between TMPRSS2:ERG fusion and morphological features of prostate 
cancer has produced diverging results. Most studies have found no statistically significant 
association between TMPRSS2:ERG rearrangement and Gleason score, while some have 
demonstrated an association with either higher (Attard et al., 2008; Demichelis et al., 2007) 
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or lower Gleason scores (Fine et al., 2010; Gopalan et al., 2009). Taken together, it seems like 
the TMPRSS2:ERG fusion gene is an early event related to development of prostate cancer 
rather than a marker for progressive disease. Of note, the TMPRSSE:ERG fusion has 
potential for noninvasive prognosis of prostate cancer. Although RNA-based urinary tests 
demonstrate in general a high specificity and sensitivity to detect prostate cancer, no 
significant relationship was found between the presence of fusion transcripts and Gleason 
score or clinical stage (Hessels et al., 2007; Rice et al., 2010). 
3.3 Loss of heterozygosity 
The loss of heterozygosity (LOH) is a frequent genetic alteration in prostate cancer, in 
particular on chromosome arms 7q, 8p, 10q, 12p, 13q, 16q, 17q and 18q (Dong, 2006). Studies 
on chromosomal deletions of 8p22 by fluorescence in situ hybridization technique revealed 
8p22 deletion to be the strongest parameter to predict disease progression in patients 
undergoing surgery (Matsuyama et al., 2001). If some LOH have been shown to be 
associated with early stages of prostate cancer (Lu & Hano, 2008), others seem to indicate 
the presence of tumor suppressor genes whose inactivation is correlated with aggressive 
and metastatic tumors (Dong et al., 2000; Kibel et al., 2000; Matsuyama et al., 2007). A recent 
study reported the development of a noninvasive method to detect early stages of prostate 
cancer using LOH analysis of 7q31, 8p22, 12p13, 13q14, 16q23.2 and 18q21. Indeed LOH 
could be found in cells from urine obtained by prostatic massage (Thuret et al., 2005). In 
patients who underwent radical prostatectomy, LOH was confirmed from the prostatic 
tissue with a concordance of 86%. This noninvasive approach warrants further investigation 
to bring pronostic information on prostate cancer aggressiveness. 
4. RNA biomarkers 
4.1 PCA3 
PCA3 (formerly known as DD3) is a non-coding RNA very prostate specific (Bussemakers et 
al., 1999; de Kok et al., 2002). PCA3 mRNA levels can be measured in the urine specimens 
and several studies have shown that the PCA3 score is superior to serum PSA for predicting 
biopsy outcome (Groskopf et al., 2006; Haese et al., 2008; van Gils et al., 2007). The 
relationship between PCA3 score and parameters of cancer aggressiveness has also been 
studied and differ. Some studies report a positive relationship between PCA3 scores and 
parameters of more serious disease (Nakanishi et al., 2008; Whitman et al., 2008), while other 
studies could not find such a relationship (Hessels et al., 2010). Further studies are requested 
to evaluate the potential of PCA3 testing as prognostic test for prostate cancer. 
4.2 AMACR 
ǂ-methylacyl-CoA racemase (AMACR) is a catalyst in the peroximal beta-oxidation of 
branched chain fatty acids found in dietary sources (Wanders et al., 2001), such as red meat 
and dairy products, the consumption of which has been associated with increased prostate 
cancer risks (Hsing & Chokkalingam, 2006). AMACR has been identified as a potential 
biomarker based on its overexpression in localized prostate cancer as compared to benign 
prostate epithelium (Luo et al., 2002; Rhodes et al., 2002; Rubin et al., 2002). In fact, 
immunostaining for AMACR is commonly performed in prostate biopsies to help 
distinguish benign from malignant tissue. Of note, AMACR expression was found 
consistently lower both at the transcriptional (cDNA expression arrays and RT-PCR) and at 
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the protein level (immunohistochemistry and western-blot) in metastatic prostate cancer 
compared to localized prostate cancer (Kuefer et al., 2002; Rubin et al., 2004). An association 
between low AMACR protein expression at diagnosis and an increased risk of biochemical 
recurrence and fatal prostate cancer was reported in patients diagnosed with a localized 
prostate cancer who underwent radical prostatectomy or not (Rubin et al., 2005). Recent 
findings from the same group confirmed that down-regulation of AMACR expression is 
associated with poorer outcomes in a cohort of 920 men diagnosed with prostate cancer. 
However the lack of statistical significance suggests that tumor AMACR expression at 
diagnosis is not a useful prognostic biomarker for lethal disease after treatment (Barry et al., 
2011). Although AMACR protein can been detected in urine by western-blot, its 
concentration is low in serum, making the development of a serum test difficult (Rogers et 
al., 2004). Circulating concentrations of AMACR mRNA in urine or serum quantified by RT-
PCR have been found elevated in patients but these pilot studies are limited to small series 
(Zehentner et al., 2006; Zielie et al., 2004).  
4.3 MicroRNAs 
MicroRNAs are small RNAs found to regulate mRNA function by modulating both 
mRNA stability and the translation of mRNA into protein. Their expression is commonly 
altered in solid tumors and multiple microRNAs have been shown to have oncogenic 
properties or act like tumor suppressor genes. Besides their therapeutic potential, 
microRNAs hold unique characteristics that herald them as ideal tumor markers 
including their stability and ease of detection (Heneghan et al., 2010). Despite the large 
body of work that has been published to date, only limited information is available 
regarding the expression levels of specific microRNAs in relation to the aggressiveness of 
prostate cancer. Taking advantage of the stability of tumor-derived microRNAs in 
circulating blood, Mitchell and co-workers found a remarkably higher level of miR-141 
(46-fold increase) in a patients with metastatic prostate cancer compared to healthy 
control men (Mitchell et al., 2008). The first evidence of a possible prognostic relevance of 
microRNAs in prostate cancer was obtained from a study examining the tissue expression 
of 40 patients undergoing prostatectomy. The increased expression of miR-135b and miR-
194 was associated with biochemical recurrence within 2 years of surgery (Tong et al., 
2009). Another study, conducted on matched tumor and adjacent normal tissues obtained 
from 76 patients, found that high expression of miR-96 was associated with cancer 
recurrence after radical prostatectomy, and that prognostic information was confirmed by 
an independent tumor sample set from 79 pateints (Schaefer et al., 2010). The miR-221 
expression is also progressively reduced in aggressive prostate cancer and metastasis and 
predicts clinical recurrence in patients (n=92) undergoing radical prostatectomy (Spahn et 
al., 2010). More recently, miR-143 and miR-145 were identified as being associated with 
bone metastasis of prostate cancer and involved in the regulation of epithelial-
mesenchymal transition (Peng et al., 2011). Interestingly, the loss of miR-101 expression 
during cancer progression in human tumors has been associated with overexpression of 
histone methytransferase EZH2 (enhancer of zeste homolog 2) (Varambally et al., 2008). 
Amounts of both EZH2 mRNA and EZH2 protein are increased in metastatic prostate 
cancer; in addition, clinically localized prostate cancers that express higher concentrations 
of EZH2 show a poorer prognosis (Varambally et al., 2002). In cancer cell lines, the 
expression and function of EZH2  are inhibited by miR-101 (Varambally et al., 2008). 
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Thus, dysregulated expression of EZH2 may be involved in the progression of prostate 
cancer, and miR101 might represent a marker that distinguishes indolent prostate cancer 
from those at risk of lethal progression  
5. Other potential biomarkers 
5.1 Metabolomics 
Metabolite profiling or metabolomics, the analysis of endogenous metabolites in a biological 
system was recently suggested to be a promising approach to identify novel metabolites or 
their changes (Fredolini et al., 2010). In practice, however, analysis of the metabolome is 
complex because of the large range of detectable metabolites. By screening 110 samples from 
men’s urine and blood and 42 tissue samples, Chinnaiyan and collaborators recently 
identified 1,126 metabolites. They identified 87 that distinguish normal prostate from 
prostate cancer, then narrowed down the list to 6 whose levels were higher in samples 
linked to localized prostate cancer and higher still in metastatic disease (Sreekumar et al., 
2009). Sarcosine, an N-methyl derivative of the amino acid glycine, was identified as a 
differential metabolite that was highly increased during prostate cancer progression to 
metastasis. Surprisingly, the authors also provided evidence using cell cultures for a 
functional role of sarcosine in promoting invasive properties in these cells, whereas 
lowering the level of the enzyme producing sarcosine reduces invasiveness (Sreekumar et 
al., 2009). The potential role of urinary was reevaluated in another study, which showed that 
sarcosine in urine after digital rectal examination fails as a marker in prostate cancer 
detection and identification of aggressive tumors (Jentzmik et al., 2010). In addition to this 
work, the same group showed no correlation with sarcosine level in tissues and tumor stage, 
tumor grade or biochemical recurrence in 92 samples obtained after radical prostatectomy 
(Jentzmik et al., 2011). Although the lack of metastatic tissue samples was a limitation, this 
study establishes that sarcosine measurement in prostate tissue is not suitable to predict 
cancer aggressiveness or biochemical progress. 
5.2 Disseminated tumor cells 
The shedding of tumor cells into the circulation is a necessary condition for metastasis 
dissemination and the clinical relevance of the detection of disseminated tumors cells 
(DTCs) in bone marrow (the most prominent metastatic site in prostate and breast cancer) 
or in peripheral blood of patients free of apparent metastasis in under investigation. So 
far, only large breast cancer studies have confirmed the independent prognostic value of 
the bone marrow status (Berg et al., 2007). Recent studies have demonstrated an 
association between DTCs in bone marrow at diagnosis of nonmetastastic prostate cancer 
(Berg et al., 2007; Kollermann et al., 2008). Although a DTC-positive bone marrow status 
was associated with grading and increased risk of metastasis, the study by Berg et al. on 
266 patients did not find a correlation of DTC detection and survival (Berg et al., 2007). In 
contrast, Köllermann et al. demonstrated the prognostic relevance of DTCs in bone 
marrow patients with clinically localized prostate cancer submitted to neo-adjuvant 
hormonal therapy followed by radical prostatectomy and a median follow-up of 44 
months (Kollermann et al., 2008). This study is the first one on a large series of patients 
with sufficient long follow-up to clearly demonstrate an adverse prognostic effect of the 
presence of DTCs at the time of initial diagnostic.  
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Markers Strategy  of Detection Comments 
   
PSCA 
RT-PCR (blood),  
Protein expression (tissue) 
Potential therapeutic target  
   
PSP94 
ELISA (blood), 
Protein expression (tissue) 
One of the major secretory 
proteins of the prostate gland 
   
ECPA/ECPA-2 
ELISA (blood), 
Protein expression (tissue) 
 
   
uPA/uPAR 
ELISA (blood), 
Protein expression (tissue) 
uPAR expression in DTCs (bone 
marrow, peripheral blood), 
Potential therapeutic target  
   
Epigenetic markers 
(eg. GSTP1) 
Methylation specific PCR 
(blood, urine)  
Potential Multiplex test with other 
urine biomarkers 
   
Gene fusion proteins 
(eg. TMPRSS2 :ERG) 
RT-PCR (urine) 
FISH (tissue) 
Potential Multiplex test with other 
urine biomarkers  
   
Loss of heterozygoty PCR (blood, urine)  
   
PCA3 
Transcription-mediated 
amplification assay (urine) 
Potential Multiplex test with other 
urine biomarkers 
   
AMACR 
RT-PCR (blood, urine)  
Protein expression (tissue) 
Potential Multiplex test with other 
urine biomarkers, 
Potential therapeutic target 
   
MicroRNAs 
RT-PCR (blood, urine, 
tissue)  
Potential therapeutic targets 
   
Metabolomics Profiling (urine, blood)  
   
Disseminated Tumor Cells
Enumeration (blood, bone 
marrow) 
 
   
Table 1. Potential biomarkers and their strategy of detection 
Despite bone marrow analysis provides important information, peripheral blood studies are 
more acceptable in the clinical management than invasive BM aspirations. However, 
identification of circulating tumor cells (DTCs) require extremely sensitive analytical 
methods that are usually combined with enrichment procedures. Although promising 
results from patients with advanced stages demonstrate the value of CTCs technology 
(currently evaluated and validated in clinical trials as a predictor and surrogate endpoint of 
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treatment response), studies on patients at earlier stages are hampered by the low CTC 
counts. A recent study from Haber and collaborators shows that tumor cells obtained from 
the blood of cancer patients were monitored before and after surgery, most circulating cells 
rapidly declined shortly after surgery while others persisted months thereafter, suggesting 
that postoperative CTCs might derive from preestablished non prostatic sites of disease that 
continue to shed CTCs into the circulation (Stott et al., 2010). If confirmed, these 
observations support the potential application of CTC monitoring as a marker of invasive 
localized disease before the establishment of viable metastatic lesions.  
6. Conclusion  
We have here attempted to give some examples of potential DNA-based, RNA-based and 
protein-based markers of aggressiveness in prostate cancer. Comparisons between studies 
are often difficult because of some inconsistencies between study cohorts, collection 
methods and handling of samples. It is unlikely that a single biomarker (evaluated on 
conventional approach looking at a single molecular predictor significantly up- or down-
regulated) will provide the information requested to tell how aggressive a diagnosed 
prostate cancer is. New research methods (proteomics, metabolomics…) are also emerging, 
and high-throughput technologies will facilitate biomarker discovery. Therefore, future 
advances in this field will probably have to integrate proteomics, transcriptomics and 
multiplex approaches and identify combinations of multiple biomarkers in order to improve 
the characterization of aggressive prostate cancers. 
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